Physician profile
Christopher S Roman
NPI 1558564310
$1,124.61
in general payments reported to CMS, 2019-2025
19 companies · $104 in 2025
The $104 reported for 2025 was more than what a typical Emergency Medicine provider received nationally (typical 2025 total: $57.10).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $16.39 · 2022: $371 · 2023: $383 · 2024: $250 · 2025: $104.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $737.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $737.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $141.47 | 2022-2024 | Breztri, Airsupra, Farxiga |
| Glaxosmithkline, LLC. | $137.14 | 2022-2024 | Trelegy Ellipta, Arexvy, Nucala |
| Janssen Pharmaceuticals, INC | $126.44 | 2022-2023 | Xarelto |
| Exact Sciences Corporation | $109.93 | 2023-2025 | Cologuard Collection Kit |
| Pfizer INC. | $98.74 | 2022-2024 | |
| Abbvie INC. | $74.00 | 2022-2024 | Vraylar |
| Novo Nordisk INC | $69.05 | 2023-2024 | Saxenda, Wegovy, Rybelsus |
| Bayer Healthcare Pharmaceuticals INC. | $64.61 | 2022-2023 | |
| Lilly USA, LLC | $51.99 | 2023-2025 | Jardiance, Mounjaro, Zepbound |
| Dexcom, INC. | $42.86 | 2023 | Dexcom G6 Transmitter |
| Mylan Specialty L.P. | $40.98 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $30.76 | 2019-2022 | |
| Verona Pharma, INC. | $27.57 | 2025 | Ohtuvayre |
| Regeneron Healthcare Solutions, INC. | $23.03 | 2022 | |
| Optinose US, INC. | $20.85 | 2023 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viatris Specialty LLC | $19.11 | 2025 | Yupelri |
| Seqirus USA INC | $17.42 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $15.91 | 2022 | |
| Amgen INC. | $12.75 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Roman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.